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The novel coronavirus 2019 (COVID-19) has presented an unexpected pandemic that has triggered severe panic among 
people worldwide. In this direction, nations are maximizing their efforts to battle the disease and lower illness. Plants that 
produce numerous bioactive compounds might help develop and keep immunity against chronic diseases and COVID-19. 
Medicinal plant-based treatments are trendy in rural and tribal communities, mainly as an outcome of the increased 
scalability, which causes them to be cheaper and affordable compared to present-day medication. Furthermore, additional 
research on the antiviral possibility of healing plants shown that plant extracts with incredibly energetic secondary 
metabolites are competent to interrupt the replication of numerous very pathogenic viruses. But the testing and clinical trials 
take a very long time. This review discusses the gap in clinical studies with available phytochemicals and the possible ways 
to cover the same. 
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Present unprecedented coronavirus pandemic declared 
by the World Health Organization (WHO) is liable for 
exponential development of healthcare interest in 
coronaviruses globally
1
. Coronaviruses (CoVs) are a 
member of the family Coronaviridae and can infect both 
humans and animals
2
. Based on their serological  
and genotypic characteristics, the -coronaviruses and 
-coronaviruses genera of Coronaviridae family  
have practically every coronavirus which can infect 
humans
3
. The observed symptoms in infected individuals 
were fever, pulmonary infiltration, hypoxemia, 
thrombocytopenia, lymphopenia, leucopenia, dyspnea, 
diarrhoea, myalgia, headache, cough, and disturbed renal 
and hepatic function resulting in death in certain 
individuals
4
. Nevertheless, there exists no remedy, drug, 
or perhaps vaccine for the healing of COVID-19
5
. 
Naturally occurring phytochemicals offer a powerful 
and valuable aid of chemical elements displaying 
antiviral properties. Additional chemical modification of 
these components, guided by computer-based docking 
simulations, may additionally boost their potency or 
selectivity
6,7
. Several of the important phytochemicals 
that show promise for the healing of coronavirus in 
people consist of, polyphenols, lectin, silvestrol, and 
psoralidin
8
. Needless to point out, these compounds 
might be harmful at specific levels, and thus in vitro and 
in vivo testing is necessary to choose therapeutic and 
safe classes for every combination before medical trials 
in people are performed
9
. Initial studies might 
concentrate on compounds that have been accredited for 
medication consumption in the past and are viewed as 
protected by national organizations and the situation for 
several polyphenolic compounds
10
. It ishopeful that 
researchers are instructed by this info offered here to 
build safe, effective anti-coronavirus healing agents 
from obviously derived ingredients. 
Furthermore, standard herbal medicines and purified 
items that are organic might steer the enhancement of 
novel antiviral drugs
11
. Additionally, in the current 
outbreak of COVID-19, a lot of people appear to be 
looking at complementary or perhaps even traditional 
healing treatments, albeit using them pretty much 
entirely together with western medicine
12,13
. 
Nevertheless, dependent on the substantial scientific 
tests done on this specific topic, it is hard to sort the 
probable effects of, and interaction between, traditional 
natural medicine and western medicine
14
. In this 
direction, several studies have highlighted the role of 
traditional Chinese medications as a potential cure 
against COVID-19
15
. Broad-spectrum of the activities of 
phytochemicals can have multiple healing potentials.  
It is hoped the information given might guide the 










. Molecular docking with molecular 
dynamics simulation is commonly applied to screen 
prospective drug candidates against COVID-19. 
Literature is full of reports on the efficacy of 
phytochemicals against COVID-19. Consequently, with 
the claim that these compounds are possible anti-
COVID drugs; thus, the researcher within this area must 
confirm the working with in vitro experimental methods 
and further confirmation with the large-scale clinical 
trials
17-21
. This review highlights the gaps in clinical 
studies with phytochemicals as well as the possible ways  
to go over the same (Fig. 1). 
 
Gaps in Clinical Studies  
A comparative analysis was performed to compute 
the program amount of countless experimental 
medicines recognized in China, determined by the 
present treatment techniques, together with talking 
about recently published literature on COVID-19 
pandemic
22
. Nevertheless, it has been discovered that 
several plant species are used for a substantial amount 
of time in dealing with infectious diseases. In this 
direction, two regular Chinese natural medicines' Sang 
Ju Yin' and' Yu Ping Feng San' were utilized to observe 
the modifications of the defense system in total variety 
cellular, and the realization demonstrated that it might 
alter T cells that help boost up the vast variety 
safeguard capacity
23,24
. Furthermore, these excellent 
traditional Chinese medicine outcomes under 
controlled healthcare trials were also supported  
by lab primarily based in vitro study
25,26
. On yet 
another hand, additional scientific tests must shed light 
on the devices and pathways targeted by such things, 
which will help to improve their medical usefulness. 
Moreover, detailed studies are needed to prove the 
benefits of medicinal compounds because of the 
absence of clinical trials (or maybe minimal evidence) 
or perhaps because of research not necessarily 
introduced to COVID-19 patients
27,28
. This astonishing 
discrepancy between phytochemicals reported by 
researchers as a potential cure of COVID-19, as well as 
the apparent lack of readily available information in the 
form of national recommendations, is astonishing, and 
this is preventing the large-scale utilization of plant-
based cures
12
. In this direction, a survey of the 
ClinicalTrials.gov trial registry database showed that 
there are in total 9 trials at the different phase and only 
one is completed with the use of Brazilian green 
propolis rest all are in the recruiting, not yet recruiting 
and enrolling stage (Table 1). Furthermore, there were 
1,258 studies with the use of plant-based cure in the 
entire database, and only 9 were under evaluation for 
the COVID-19. Overall, there were 3,849 studies 
undergoing trials for the COVID-19 as of November 
2020. Whereas, based on the survey of Chinese clinical 
trial registry database (http://www.chictr.org.cn/index. 
aspx) showed only 3 studies using the plant-based cure 
for COVID-19 (Table 2). This disparity between them 
against treating organic cures as the red-headed 
stepchild of supporting cancer care as well as for 
(re)assessing which plants-based treatment will be 
advised based on their backing by large scale clinical 
trials. 
 
Sealing the Gap 
Trial methods may be substantially improved to 
increase the medical value and common comfort of 
trial results, by incorporating subjects from usually 
underrepresented sociodemographic groups as well as 
employing more naturalistic techniques considerably 
to treatment, performing more comparison trials as 
compared to most acceptable available approaches, 
growing the uses of trials to contend with interventions 
beyond chemotherapeutics, along with improving 
methods for looking at the long-term effects of 
treatment
29,30
. The problem of generalizability is 
frequently viewed as the primary limitation of 
randomized trials
31
. Therefore, the trial results may vary 
significantly less applicable to many treatment choices, 
though the people there have the same signs and 
symptoms
32
. Also, consider whether a person has 
comorbid situations or perhaps an increased risk of bad 
outcomes attributable to things beyond the natural 
characteristics of the state, which will influence the 
possible risks and benefits of treatment
33
. 
One specific area where there might be 
enhancement is in a broader representation of people 
from different racial and cultural organizations
34
. The 
generalizability of trial advantages would similarly  
be enhanced by participation in a far better quantity of  
 
 
Fig. 1 — A summary of the methodology used to identify the 
most effective phytochemicals against COVID-19 





Table 1 — List of plant-based studies identified from a survey of the ClinicalTrials.gov trial registry database as of December 2020 
Sl. No Status Study Title Conditions Interventions 
1 Recruiting Randomized Proof-of-Concept Trial to 
Evaluate the Safety and Explore the 
Effectiveness of a Plant Polyphenol  
for COVID-19 
COVID-19 Drug: Plant Polyphenol 
Dietary Supplement: Vitamin D3 
2 Enrolling by 
invitation 
Phytomedicines Versus 
Hydroxychloroquine as an Add on 
Therapy to Azythromycin in 
Asymptomatic COVID-19 Patients 






3 Completed The Use of Brazilian Green Propolis 
Extract (EPP-AF) in Patients Affected  
by COVID-19 
COVID-19 Drug: Brazilian Green  
Propolis Extract (EPP-AF) 
Other: Standard care 
4 Not yet 
recruiting 
COVID-19: Collecting Measurements of 
Renin-angiotensin-system Markers, Such 
as Angiotensin-2 and Angiotensin 1-7 
COVID-19 Combination Product: Tomeka® 
Drug: "Vernonia amygdalina" 
5 Recruiting The Effect of Aromatherapy on  
COVID-19-induced Anxiety 
Stress COVID-19 Anxiety Other: Essential Oil Blend 
Other: Control Blend 
6 Recruiting Describing Chinese Herbal Medicine 
Telehealth Care for Symptoms Related to 
Infectious Diseases Such as COVID-19 
Coronavirus  
Infection 
Dietary Supplement: Chinese Herbal 
Medicine 
7 Not yet 
recruiting 





Dietary Supplement: CBD Isolate 
Dietary Supplement: Full Spectrum CBD 
Oil 
Dietary Supplement: Placebo Oil 
8 Not yet 
recruiting 
Effect of a Nss to Reduce Complications 
in Patients With COVID-19 and 




Dietary Supplement: Nutritional support 
system (NSS) 
Other: Control 
9 Recruiting Outcomes Mandate National Integration 
With Cannabis as Medicine for 
Prevention and Treatment of COVID-19 
COVID-19 
Chronic Pain 
Chronic Pain Syndrome 
Chronic Pain Due to Injury 
Drug: Cannabis, Medical 
 
Table 2 — List of plant-based studies identified from a survey of Chinese clinical trial registry database 
(http://www.chictr.org.cn/index.aspx) as of December 2020 
Registration number Public title Type Registration Date 
ChiCTR2000030503 Extracorporeal blood purification therapy using Li's Artifical Liver System 
for patients with severe novel coronavirus pneumonia (COVID-19) patient 
Interventional 2020/03/05 
ChiCTR2000030223 Quality of life among Chinese residents during and after novel coronavirus 
pneumonia (COVID-19) outbreak: an online survey 
- 2020/02/26 
ChiCTR2000030215 Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of 
novel coronavirus pneumonia (COVID-19) 
Interventional 2020/02/25 
 
coaching sorts among recruiting facilities for medical 
trials
35
. Nevertheless, medical studies of far more 
prevalent problems would acquire from that 
diversification. A variety of novel trial styles happen 
to be suggested to handle this problem and 
additionally to enhance the participation of subjects 
who might not ordinarily get engaged in a clinical 
trial since they are uncomfortable with the idea of 
remaining randomly given to treatment
36
. The 
utilization related to a second "rescue" medicine in 
case an issue does not react to the initial therapy is 
going to be an example associated with a fixed 
adaptive design. A mostly randomized affected 
individual preference layout trial is similar in that 
subjects could select the treatment of theirs
37
. In an 
attempt on the invention, the possibility of choosing a 




chosen therapy or perhaps which makes it easy for 
themselves to be randomized. The big, simple trial 
paradigm is a substitute for these novel versions
38
. 
The gains associated with an extensive, simple trial 
will be its inclusiveness, value to the usual workout 
atmosphere, and a naturalistic approach to therapy. 
 
Conclusion 
Naturally occurring phytochemicals provide a 
valuable and powerful aid of synthetic parts displaying 
antiviral properties. It is hoped that this information 
instructs researchers offered right here in the technique 
of creating safe, highly productive anti coronavirus 
healing parts from naturally derived ingredients. Instead, 
our goal is usually to collate information over the 
wonderful spectrum of excellent phytochemicals from a 
selection of plant species that might have healing 
potential. A great deal of novel trial kinds happens to be 
backed by handling this material and to improve the 
participation of subjects which would more than likely 
not ordinarily get interested in a clinical trial since 
they're uncomfortable with the idea of trying to keep 
arbitrarily provided to therapy. The utilization associated 
with a second "rescue" medicines in case an issue 
doesn't react to the initial treatment is going to be a great 
case related to a fixed adaptive style. A usually 
randomized affected personal preference layout trial is 
reasonably similar in that subjects might choose their 
healing of theirs. Phytochemicals are readily available 
near households and are widely domesticated throughout 
even in the world's semi-arid and dry regions. Due to 
numerous bioactive compounds in their leaves, fruit, 
etc., including vitamins, polyphenols, and amino acids. 
It is only because of the critical need for therapeutic 
interventions for COVID-19, caused by the SARS-
Coronavirus, that so much attention is needed  
right now to repurposed not only antiviral drugs but also 
to natural products and herbal medications. 
Alternatively, it may serve as a springboard for future 
clinical trials examining the efficacy of several 
commercially available phytochemical supplements in 
improving the health status of COVID-19 patients, as 
well as for experimental studies characterizing the 
aforementioned ligand–protease interaction. 
Furthermore, extra exploration on the antiviral chance 
of healing plant life disclosed that plant extracts with 
extremely lively secondary metabolites are adept at 
disrupting the replication of many extremely pathogenic 
viruses. Nevertheless, clinical trials and testing may  
have genuine time. Moreover, for dealing with the issues 
like biopiracy, the nation ought to bioprospecting  
its ethnomedicinal understanding wherein local 
communities and indigenous people must be the  
primary element. Their knowledge and voices must be 
mirrored in the decision-making procedures. Traditional 
medication-based bioprospecting would supply 
unmatched eco-friendly chemical substances and their 
promising brand-new leads. It is time to be vocal about 
local items and helps these hometown items to be global. 
Cross-cultural knowledge of medicinal plants and their 
therapeutic uses could further intensify the development 
of more affordable, effective, and safer medicines  
against COVID-19. To be able to commercialize novel 
formulations at a worldwide level, the nation must be 
vocal towards traditional knowledge. 
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